S&P 500   3,919.82 (+0.99%)
DOW   31,957.41 (+1.33%)
QQQ   322.80 (+0.41%)
AAPL   124.53 (-1.06%)
MSFT   233.88 (+0.26%)
FB   265.26 (-0.23%)
GOOGL   2,077.96 (+0.87%)
AMZN   3,152.66 (-1.31%)
TSLA   726.07 (+3.90%)
NVDA   576.90 (+1.98%)
BABA   249.49 (-1.29%)
CGC   35.36 (+0.14%)
GE   13.27 (+5.40%)
MU   91.08 (+3.23%)
NIO   50.61 (+3.05%)
AMD   86.15 (+1.66%)
T   29.30 (+0.41%)
F   12.18 (+4.82%)
ACB   11.32 (+0.98%)
DIS   197.27 (+0.09%)
BA   226.57 (+6.81%)
NFLX   551.32 (+0.95%)
BAC   36.41 (+2.51%)
S&P 500   3,919.82 (+0.99%)
DOW   31,957.41 (+1.33%)
QQQ   322.80 (+0.41%)
AAPL   124.53 (-1.06%)
MSFT   233.88 (+0.26%)
FB   265.26 (-0.23%)
GOOGL   2,077.96 (+0.87%)
AMZN   3,152.66 (-1.31%)
TSLA   726.07 (+3.90%)
NVDA   576.90 (+1.98%)
BABA   249.49 (-1.29%)
CGC   35.36 (+0.14%)
GE   13.27 (+5.40%)
MU   91.08 (+3.23%)
NIO   50.61 (+3.05%)
AMD   86.15 (+1.66%)
T   29.30 (+0.41%)
F   12.18 (+4.82%)
ACB   11.32 (+0.98%)
DIS   197.27 (+0.09%)
BA   226.57 (+6.81%)
NFLX   551.32 (+0.95%)
BAC   36.41 (+2.51%)
S&P 500   3,919.82 (+0.99%)
DOW   31,957.41 (+1.33%)
QQQ   322.80 (+0.41%)
AAPL   124.53 (-1.06%)
MSFT   233.88 (+0.26%)
FB   265.26 (-0.23%)
GOOGL   2,077.96 (+0.87%)
AMZN   3,152.66 (-1.31%)
TSLA   726.07 (+3.90%)
NVDA   576.90 (+1.98%)
BABA   249.49 (-1.29%)
CGC   35.36 (+0.14%)
GE   13.27 (+5.40%)
MU   91.08 (+3.23%)
NIO   50.61 (+3.05%)
AMD   86.15 (+1.66%)
T   29.30 (+0.41%)
F   12.18 (+4.82%)
ACB   11.32 (+0.98%)
DIS   197.27 (+0.09%)
BA   226.57 (+6.81%)
NFLX   551.32 (+0.95%)
BAC   36.41 (+2.51%)
S&P 500   3,919.82 (+0.99%)
DOW   31,957.41 (+1.33%)
QQQ   322.80 (+0.41%)
AAPL   124.53 (-1.06%)
MSFT   233.88 (+0.26%)
FB   265.26 (-0.23%)
GOOGL   2,077.96 (+0.87%)
AMZN   3,152.66 (-1.31%)
TSLA   726.07 (+3.90%)
NVDA   576.90 (+1.98%)
BABA   249.49 (-1.29%)
CGC   35.36 (+0.14%)
GE   13.27 (+5.40%)
MU   91.08 (+3.23%)
NIO   50.61 (+3.05%)
AMD   86.15 (+1.66%)
T   29.30 (+0.41%)
F   12.18 (+4.82%)
ACB   11.32 (+0.98%)
DIS   197.27 (+0.09%)
BA   226.57 (+6.81%)
NFLX   551.32 (+0.95%)
BAC   36.41 (+2.51%)
Log in
NASDAQ:NVAX

Novavax Stock Forecast, Price & News

$237.70
-5.53 (-2.27 %)
(As of 02/24/2021 02:57 PM ET)
Add
Compare
Today's Range
$235.00
Now: $237.70
$252.00
50-Day Range
$116.24
MA: $200.81
$319.93
52-Week Range
$6.77
Now: $237.70
$331.68
Volume51,375 shs
Average Volume5.09 million shs
Market Capitalization$15.13 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.01
Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen. The company is also developing RSV F vaccine for older adults (60 years and older) that is in Phase II clinical trial, as well as for healthy children between six months to five years of age that is in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus that is in Phase I clinical trial; and combination respiratory vaccine to protect against influenza and RSV. Further, the company is developing COVID-19 vaccine for coronavirus that causes pneumonia-like symptoms, which is in preclinical stage. It has a partnership agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:NVAX
CUSIP67000210
Phone240-268-2000
Employees522
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.66 million
Book Value($5.75) per share

Profitability

Net Income$-132,690,000.00
Net Margins-133.10%

Miscellaneous

Market Cap$15.13 billion
Next Earnings Date3/1/2021 (Confirmed)
OptionableOptionable

MarketRank

Overall MarketRank

1.18 out of 5 stars

Medical Sector

851st out of 1,958 stocks

Biological Products, Except Diagnostic Industry

112th out of 177 stocks

Analyst Opinion: 1.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$237.70
-5.53 (-2.27 %)
(As of 02/24/2021 02:57 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Novavax (NASDAQ:NVAX) Frequently Asked Questions

Is Novavax a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last twelve months. There are currently 1 sell rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Novavax stock.
View analyst ratings for Novavax
or view top-rated stocks.

What stocks does MarketBeat like better than Novavax?

Wall Street analysts have given Novavax a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Novavax wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Novavax's next earnings date?

Novavax is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Novavax
.

How can I listen to Novavax's earnings call?

Novavax will be holding an earnings conference call on Monday, March 1st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) released its quarterly earnings results on Monday, November, 9th. The biopharmaceutical company reported ($3.21) earnings per share for the quarter, missing the consensus estimate of $2.36 by $5.57. The biopharmaceutical company earned $157 million during the quarter, compared to analyst estimates of $230.56 million. Novavax had a negative net margin of 133.10% and a negative trailing twelve-month return on equity of 1,346.17%. The business's revenue was up 6180.0% compared to the same quarter last year.
View Novavax's earnings history
.

How has Novavax's stock been impacted by COVID-19 (Coronavirus)?

Novavax's stock was trading at $10.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NVAX stock has increased by 2,161.2% and is now trading at $237.65.
View which stocks have been most impacted by COVID-19
.

When did Novavax's stock split? How did Novavax's stock split work?

Shares of Novavax reverse split before market open on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for NVAX?

7 brokerages have issued 12 month target prices for Novavax's shares. Their forecasts range from $38.50 to $338.00. On average, they anticipate Novavax's stock price to reach $213.93 in the next year. This suggests that the stock has a possible downside of 10.0%.
View analysts' price targets for Novavax
or view top-rated stocks among Wall Street analysts.

Who are Novavax's key executives?

Novavax's management team includes the following people:
  • Mr. Stanley Charles Erck, Pres, CEO & Director (Age 73, Pay $1.45M)
  • Mr. John A. Herrmann III, Exec. VP, Chief Legal Officer & Corp. Sec. (Age 55, Pay $865.02k)
  • Dr. Gregory M. Glenn, Pres of R&D (Age 67, Pay $1.06M)
  • Mr. John Joseph Trizzino, Exec. VP, Chief Bus. & Commercial Officer & Treasurer (Age 61, Pay $881.5k)
  • Mr. Gregory F. Covino, Exec. VP & CFO (Age 55)
  • Mr. Richard P. Crowley, Exec. VP & COO (Age 64)
  • Mr. Biegie Lee, Sr. VP & Chief Information Officer
  • Ms. Silvia Taylor M.B.A., MBA, Sr. VP of Investor Relations & Corp. Affairs
  • Ms. Erika S. Trahan, Associate Director of Investor & PR
  • Mr. Sven Andreasson M.B.A., Sr. VP of Corp. Devel. (Age 69)

What is Stanley C. Erck's approval rating as Novavax's CEO?

46 employees have rated Novavax CEO Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among Novavax's employees.

Who are some of Novavax's key competitors?

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Palo Alto Networks (PANW), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Who are Novavax's major shareholders?

Novavax's stock is owned by many different institutional and retail investors. Top institutional shareholders include Northern Trust Corp (1.48%), Nuveen Asset Management LLC (0.78%), Charles Schwab Investment Management Inc. (0.62%), Price T Rowe Associates Inc. MD (0.54%), Bank of New York Mellon Corp (0.47%) and Jennison Associates LLC (0.35%). Company insiders that own Novavax stock include Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck.
View institutional ownership trends for Novavax
.

Which major investors are selling Novavax stock?

NVAX stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Hellman Jordan Management Co. Inc. MA, Squarepoint Ops LLC, Alliancebernstein L.P., Baker BROS. Advisors LP, ETF Managers Group LLC, TSP Capital Management Group LLC, and Avantax Advisory Services Inc.. Company insiders that have sold Novavax company stock in the last year include Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, and Stanley C Erck.
View insider buying and selling activity for Novavax
or view top insider-selling stocks.

Which major investors are buying Novavax stock?

NVAX stock was acquired by a variety of institutional investors in the last quarter, including Northern Trust Corp, Price T Rowe Associates Inc. MD, WBI Investments, Panagora Asset Management Inc., Jennison Associates LLC, Nordea Investment Management AB, First Trust Advisors LP, and Van ECK Associates Corp. Company insiders that have bought Novavax stock in the last two years include Gregory M Glenn, James F Young, and Rachel K King.
View insider buying and selling activity for Novavax
or or view top insider-buying stocks.

How do I buy shares of Novavax?

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novavax's stock price today?

One share of NVAX stock can currently be purchased for approximately $237.65.

How much money does Novavax make?

Novavax has a market capitalization of $15.13 billion and generates $18.66 million in revenue each year. The biopharmaceutical company earns $-132,690,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis.

How many employees does Novavax have?

Novavax employs 522 workers across the globe.

What is Novavax's official website?

The official website for Novavax is www.novavax.com.

Where are Novavax's headquarters?

Novavax is headquartered at 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878.

How can I contact Novavax?

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]


This page was last updated on 2/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.